 |
|
|
| |
On-treatment Viral Response to MK-5172/MK-8742 ± RBV for 12 Weeks in HCV/HIV Co-infected Patients: The C-WORTHY Study
|
| |
| |
Reported by Jules Levin
CROI 2013 March 3-6 Boston, MA
Mark Sulkowski1, Josep Mallolas2, Marc Bourliere3,
Jan Gerstoft4, Oren Shibolet5, Ronald Nahass6, Edwin DeJesus7,
Melissa Shaughnessy8, Peggy Hwang8, Barbara Haber8
1Johns Hopkins University School of Medicine, Baltimore, MD, USA; 2Hospital de Dia. Enfermedades Infecciosas, Barcelona, Spain; 3Service
d'hepato-gastroenterologie, Hopital Saint-Joseph, Marseille, France; 4Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark; 5Liver Unit, Department of Gastroenterology, Tel-Aviv Medical Center, Tel-Aviv, Israel; 6ID Care, Hillsborough, NJ, USA; 7Orlando Immunology Center, Orlando, Florida; 8Merck & Co. Inc., Whitehouse Station, NJ, USA.
|
| |
|
|
|
|
|
